0000950170-23-066796.txt : 20231129
0000950170-23-066796.hdr.sgml : 20231129
20231129164900
ACCESSION NUMBER: 0000950170-23-066796
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231127
FILED AS OF DATE: 20231129
DATE AS OF CHANGE: 20231129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bedrosian Camille L
CENTRAL INDEX KEY: 0001326969
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 231452989
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
ownership.xml
4
X0508
4
2023-11-27
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001326969
Bedrosian Camille L
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
false
true
false
false
Chief Medical Officer
false
Common Stock
2023-11-27
4
A
false
58333
0.00
A
58333
D
Stock Option (Right to Buy)
12.93
2023-11-27
4
A
false
162500
0.00
A
2033-11-26
Common Stock
162500
162500
D
The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSU shall vest in 4 annual installments, with the first installment vesting on December 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
25% of the shares subject to the option shall vest and become exercisable on December 1, 2024, with the remainder vesting in a series of 36 successive monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
/s/ Joshua B. Cohen, as Attorney in Fact
2023-11-29